Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 25, 2025 03:00 ET | Source: ITM Isotope Technologies Munich SE

ITM Announces Analyses from Phase 3 COMPETE Data Showing Higher Objective Response Rates with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus Across Subgroups of Patients with GEP-NETs at NANETS 2025 Annual Symposium

Austin, Texas, October 25, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, announced analyses data from its Phase 3 COMPETE trial in patients with Grade...
October 18, 2025 05:15 ET | Source: ITM Isotope Technologies Munich SE

ITM Announces Phase 3 COMPETE Data Demonstrating a Statistically Significant Higher Objective Response Rate with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus in Patients with Gastroenteropancreatic Neuroendocrine Tumors at ESMO 2025

Study data also showed prolonged progression-free survival with 177Lu-edotreotide compared to everolimus across patient subgroups Berlin, Germany, October 18, 2025 – ITM Isotope Technologies Munich...
October 17, 2025 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM to Announce Phase 3 COMPETE Trial Post Hoc Subgroup Analyses and Host Satellite Symposium at NANETS 2025

Garching / Munich, Germany, October 17, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that post hoc subgroup analyses data from its...
October 13, 2025 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM Appoints Annette Breunig as Chief People Officer

Global HR leader to drive ITM’s long-term human resources strategy, support organizational development and corporate growth Garching / Munich, Germany, October 13, 2025 – ITM Isotope Technologies...
October 08, 2025 06:00 ET | Source: ITM Isotope Technologies Munich SE

ITM Presents Dosimetry Data from Phase 3 COMPETE Trial Supporting Favorable Efficacy and Safety Profile with n.c.a. 177Lu-edotreotide (ITM-11) in Patients with Gastroenteropancreatic Neuroendocrine Tumors at EANM 2025 Annual Congress

Study showed targeted tumor uptake with low healthy organ exposure in broad cohort of 207 patientsSupports therapeutic potential of ITM’s proprietary targeted radiotherapeutic agentAbstract receives...
September 24, 2025 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM and TerThera Sign Supply Agreement for Medical Radioisotope Terbium-161

Garching / Munich, Germany, and Breda, the Netherlands, September 24, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and TerThera BV, a leading...
September 16, 2025 05:07 ET | Source: ITM Isotope Technologies Munich SE

ITM to Present COMPETE Dosimetry Data and Host Satellite Symposium at EANM 2025

Garching / Munich, Germany, September 16, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that it will unveil dosimetry data from its...
September 04, 2025 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM to Present at the Oppenheimer Annual Targeted Radiopharmaceutical Therapies in Oncology Summit

Garching / Munich, Germany, September 4, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced its participation in the Oppenheimer Annual...
August 19, 2025 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM to Present New Subgroup Analysis Data from the COMPETE Trial at ESMO 2025 and Host an Educational Event for Healthcare Professionals

Garching / Munich, Germany, August 19, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, today announced that further data on efficacy, safety and...
June 23, 2025 05:00 ET | Source: ITM Isotope Technologies Munich SE

ITM and Debiopharm Announce First Patient Imaged in New Study Arm of Phase 1/2 Trial Evaluating ITM-94 as Diagnostic Agent for Clear Cell Renal Cell Carcinoma (ccRCC)

New study arm (Part D) is part of the broad clinical development plan of the ITM-91/ITM-94 theranostic program in patients with Carbonic Anhydrase IX (CAIX)-expressing tumors Part D builds on...